Aimei Health Technology Co., Ltd. (AFJK) · Nov 5, 2026 · New debt
One-month extension — Deadline moved to Dec. 6, 2026 from Nov. 6; 24th permitted extension
Aimei Health’s latest extension keeps its SPAC alive through December 6, but the filing shows continued delay rather than business-combination progress.
Aimei remains a blank-check company still searching for a combination target. Its earlier United Hydrogen transaction was terminated in July 2026, leaving the SPAC with no completed deal and a shrinking runway.
This filing preserves the vehicle for one more month, but does not advance the underlying transaction story. Aimei deposited $34,330.96 into its trust account to move the termination date from November 6 to December 6, 2026. The filing calls this the 24th permitted extension, making the event more continuation than surprise.
| Current | Prior deadline | Note terms | |
|---|---|---|---|
| Extension payment (Extension Payment) | $34,330.96 | $34,330.96 | |
| Termination date (Extension Payment) | Dec. 6, 2026 | Nov. 6, 2026 | |
| Permitted extension number (Extension Payment) | 24th | 23rd | |
| Promissory note principal (Promissory Note) | $34,330.96 | Due at business combination | |
| Conversion price (Promissory Note) | $10.00 per unit |
The financing is small and sponsor-funded, but it creates no operating momentum. The non-interest-bearing note is payable when a business combination closes and can be converted into private units at $10 per unit. That structure keeps the trust funded without immediate cash repayment, while preserving potential dilution if the note converts.
The next deadline is more important than this extension itself. Shareholders were scheduled to vote on November 10, 2026 on extending the broader combination window to as late as December 6, 2027; without approval, the current December 6, 2026 deadline remains the relevant cutoff.
Bottom line: This is a routine lifeline, not evidence of a replacement deal or improved execution. It keeps Aimei alive, but after the prior transaction ended, the business-combination story remains stalled and slightly more time-sensitive.
Shareholder vote on deadline extension, November 10, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!